MARINE RESOURCES: MANAGEMENT OF DIABETES

Abstract

Diabetes mellitus, a chronic condition that may be life-threatening is a huge threat to the health of people all over the world. Conventional treatments provide only a limited number of remedies, and they often come with unintended consequences. An exceptional opportunity for the development of new anti-diabetic medicines that have strong actions and reduced side effects is presented by the huge marine environment, which has not been investigated to its full potential. Subsequent metabolites derived from marine creatures are the subject of this review, which dives into the fascinating world of secondary metabolites and highlights the many antidiabetic processes and intriguing therapeutic possibilities of these compounds.

The secondary metabolites that are produced by marine algae, sponges, fungus, and invertebrates are quite varied in terms of their structural composition. These secondary metabolites include terpenoids, alkaloids, polysaccharides, and polyphenols. One of the effects that these compounds display is the inhibition of α-glucosidase and α-amylase, as well as insulin sensitization and antioxidant activity. These compounds interact with critical targets in glucose metabolism. Phlorotannins, which are found in brown algae can effectively block α-glucosidase, which in turn delays the absorption of glucose. Sterols generated from sea stars have been shown to have insulin-sensitizing effects, whereas alkaloids obtained from fungi are responsible for maintaining glucose homeostasis. Several marine metabolites have made it to the preclinical and clinical testing stages, demonstrating their potential for use in the development of anti-diabetic therapies.

Keywords: Diabetes Mellitus, Marine-derived therapies, Bioactive compounds, Anti-diabetic properties, Insulin sensitivity, Diabetes complications.

Authors

Mr. Josef Yakin
Faculty of Pharmaceutical Science,
Assam down town University, Panikhaiti,
Guwahati, 781026 Assam- India.

Mr. Arghya Saha Choudhury
NEF College of Pharmaceutical Education & Research,
Jail Rd, Haibargaon, Fauzdaripatty, Nagaon, 782001, Assam- India.

Dr. Faruk Alam
Faculty of Pharmaceutical Science,
Assam down town University, Panikhaiti,
Guwahati, 781026 Assam- India.

Mr. Mohidul Islam
Faculty of Pharmaceutical Science,
Assam down town University, Panikhaiti,
Guwahati, 781026, Assam- India.

I. INTRODUCTION

This chapter delves into the complexities of diabetes mellitus, a chronic metabolic disorder characterized by elevated blood sugar levels. Current management strategies primarily rely on medications, insulin therapy, and lifestyle modifications. However, the ever-evolving field of medical research is exploring the potential of marine resources as a source of supplementary or alternative therapeutic options for diabetes. This chapter aims to provide a comprehensive overview of the pathophysiology of diabetes, the diverse bioactive chemicals found in marine sources [32], and the current understanding of their effectiveness in managing this global health challenge.

1. Unveiling The Pathophysiological Landscape of Diabetes Mellitus

Deconstructing Diabetes Mellitus: A Spectrum of Metabolic Disruptions: Diabetes mellitus (DM) encompasses a spectrum of metabolic disorders characterized by chronic hyperglycemia, or persistently high blood sugar. This abnormal blood sugar state results from impairments in the body's ability to produce or utilize insulin effectively.

Unveiling the Two Main Culprits: Type 1 and Type 2 Diabetes

- Type 1 diabetes: An autoimmune-mediated condition where the body's immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas, leading to absolute insulin deficiency.
- Type 2 diabetes: The most prevalent form of diabetes, characterized by insulin resistance, where the body's cells become less responsive to insulin's effects on blood sugar regulation. Additionally, a relative deficiency in insulin secretion often accompanies this resistance. Several factors, including obesity, physical inactivity, and genetic predisposition, contribute to the development of type 2 diabetes [11,18,30].

The Cascade of Complications Triggered by Hyperglycemia: Chronic hyperglycemia, a hallmark of diabetes mellitus, unleashes a cascade of detrimental effects on the body. These complications can be broadly categorized into microvascular and macrovascular complications.

- **Microvascular Complications: A Silent Threat from Within:** Microvascular complications involve damage to small blood vessels, primarily affecting the eyes (retinopathy), kidneys (nephropathy), and nerves (neuropathy). These complications can lead to vision loss, kidney failure, and debilitating nerve pain, significantly impacting quality of life.

- **Macrovascular Complications: A Looming Cardiovascular Threat:** Macrovascular complications encompass cardiovascular diseases (CVD) such as coronary artery disease, stroke, and peripheral arterial disease. Hyperglycemia contributes to the development and progression of these complications by accelerating atherosclerosis, the buildup of plaque in the arteries.

Glycemic Control: The Cornerstone of Diabetes Management: Maintaining optimal glycemic control, which refers to keeping blood sugar levels within a healthy range, is paramount in preventing or delaying the onset and progression of diabetes complications. This underscores the critical need for effective and readily accessible treatment strategies for diabetes management [12].

II. UNVEILING THE TREASURES OF THE DEEP: BIOACTIVE COMPOUNDS FROM MARINE SOURCES

1. A Glimpse into the Ocean's Bounty: Algae and Fish as Sources of Bioactive Molecules

The vast marine environment harbors a remarkable diversity of life forms, many of which are a treasure trove of bioactive compounds with potential health benefits. Algae and fish are two prominent marine sources that have garnered significant interest in the field of diabetes research due to the presence of various bioactive chemicals with anti-diabetic properties [1,32].

2. Unveiling the Chemical Arsenal: Key Bioactive Compounds in Marine Sources [27]

Marine sources are a rich reservoir of several bioactive compounds with potential anti-diabetic properties. These include:

- Polysaccharides: Complex carbohydrates found in algae with demonstrated anti-diabetic effects, including inhibiting carbohydrate-digesting enzymes and alleviating oxidative stress [26].
- Polyphenols: Antioxidant compounds naturally occurring in algae and fish, known for their ability to combat cellular damage and inflammation associated with diabetes [1,3,16].
- Peptides: Short-chain amino acid sequences derived from fish protein hydrolysates, exhibiting anti-diabetic effects by inhibiting the enzyme DPP-4 (dipeptidyl peptidase-4) and improving insulin sensitivity.
- Omega-3 Fatty Acids: Polyunsaturated fatty acids, particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), abundant in fatty fish, known for their anti-inflammatory effects and potential to enhance insulin sensitivity [8,9,14].
- Marine Sterols: A class of naturally occurring lipids found in marine organisms, demonstrating promising anti-diabetic effects in preclinical studies, with potential to modulate various pathways involved in glucose homeostasis and insulin signalling [7,22].

III. EXPLORING THE POTENTIAL: PRECLINICAL AND CLINICAL EVIDENCE FOR MARINE-DERIVED THERAPIES IN DIABETES MELLITUS

This section will delve into the scientific evidence supporting the potential of marine-derived compounds in managing diabetes [27]. We will explore findings from preclinical studies conducted in animal models and analyze the results of clinical trials investigating the efficacy of these compounds in human subjects with diabetes.

1. Preclinical Studies: Unveiling the Promise of Marine Bioactives [29,32]

Preclinical studies play a crucial role in initial investigations of potential therapeutic agents. These studies typically involve experiments conducted in cell cultures or animal models, such as rodents with chemically induced diabetes. Here, we will explore the findings of preclinical studies on marine-derived compounds with potential anti-diabetic properties.

Polysaccharides: Modulating Carbohydrate Metabolism and Reducing Oxidative Stress [26]: Preclinical studies have shown that polysaccharides derived from various marine algae exhibit promising anti-diabetic effects [31]. These effects include:

- Inhibiting alpha-amylase and alpha-glucosidase enzymes, which are responsible for breaking down carbohydrates in the digestive tract, leading to slower glucose absorption and reduced postprandial (after-meal) blood sugar spikes [16].
- Scavenging free radicals and reducing oxidative stress, a condition characterized by an imbalance between free radicals and antioxidants in the body, which plays a significant role in the development of diabetes complications [4,6].

Examples of marine polysaccharides studied preclinically for their anti-diabetic potential include fucoidan from brown algae [24,25,31], laminaran from brown algae, and ulvan from green algae [6,16].

Polyphenols: Combating Inflammation and Cellular Damage: Preclinical studies suggest that polyphenols isolated from marine sources possess anti-diabetic properties through various mechanisms [24], including:

- Dampening chronic low-grade inflammation, a hallmark of diabetes, which contributes to insulin resistance and β-cell dysfunction.
- Protecting pancreatic β-cells from oxidative stress and promoting their survival and function.
- Improving insulin sensitivity in peripheral tissues such as muscle and fat [26,30].

Examples of marine polyphenols with promising preclinical results include phloroglucinol from brown algae [25] and catechins from green tea (although green tea is not technically a marine source, it is often included in discussions of marine-derived bioactive compounds).

Peptides: Enhancing Insulin Action and Regulating Glucose Metabolism [20,28]: Preclinical research has demonstrated the potential of fish protein hydrolysates (FPH) and their constituent peptides for managing diabetes. These peptides exhibit anti-diabetic effects by:

- Inhibiting the DPP-4 enzyme, which leads to increased levels of incretin hormones, gut peptides that stimulate insulin secretion and suppress glucagon release.
- Improving insulin sensitivity in peripheral tissues, allowing cells to utilize glucose more effectively.
- Modulating enzymes involved in glucose production by the liver.

Omega-3 Fatty Acids: Optimizing Insulin Sensitivity and Cardiovascular Health [30]: Preclinical studies provide evidence that omega-3 fatty acids, particularly EPA and DHA, found abundantly in fatty fish, offer benefits for diabetes management. These benefits include:

- Enhancing insulin sensitivity and improving glucose uptake by muscle and fat cells.
- Reducing inflammation, a key contributor to insulin resistance.
- Exerting beneficial effects on blood lipids, potentially reducing the risk of cardiovascular complications associated with diabetes.

Marine Sterols: Unveiling Novel Targets for Diabetes Management: Emerging preclinical research explores the potential of marine sterols, such as fucosterol and pachysterol, for their anti-diabetic properties. These sterols appear to modulate various pathways involved in glucose homeostasis and insulin signaling, although the exact mechanisms require further investigation.

2. Clinical Trials: Translating Preclinical Promise into Patient Benefits

Clinical trials are essential for evaluating the safety and efficacy of potential therapeutic agents in human subjects with diabetes. This section will analyze the findings of clinical trials investigating the effectiveness of marine-derived compounds for diabetes management.

- **Marine Polysaccharides: Emerging Clinical Evidence [15,23,31]:** Clinical trials on marine polysaccharides for diabetes management are still in their early stages. However, some studies have shown promising results. For example, trials involving fucoidan supplementation in individuals with type 2 diabetes have demonstrated improvements in glycemic control and insulin sensitivity [19].

- **Polyphenols: Exploring Clinical Applications:** Clinical trials investigating the effects of marine polyphenols on diabetes management are limited. However, studies on general polyphenol intake suggest potential benefits for glycemic control and cardiovascular health in diabetic individuals. Further research is needed to explore the specific effects of marine-derived polyphenols.

- **Peptides: Building Clinical Evidence [20,28]:** Clinical trials investigating the anti-diabetic effects of peptides derived from fish protein hydrolysates (FPH) are yielding encouraging results. Studies have demonstrated that FPH supplementation in individuals with type 2 diabetes can lead to:
  - Improved glycemic control, as measured by reductions in hemoglobin A1c (HbA1c), a marker of long-term blood sugar control.
  - Enhanced insulin sensitivity, allowing for better utilization of blood sugar by peripheral tissues.
  - Reduced postprandial hyperglycemia, or blood sugar spikes after meals.

  These findings highlight the potential of FPH peptides as a complementary therapeutic approach for managing type 2 diabetes.

- **Omega-3 Fatty Acids: Established Clinical Benefits:** Clinical trials have established the well-documented benefits of omega-3 fatty acids, particularly EPA and DHA, for managing diabetes and its associated complications. Key findings include:
- Improved glycemic control and insulin sensitivity in individuals with type 2 diabetes.
- Reduced inflammation, a key contributor to insulin resistance and cardiovascular

complications.
- Lowered blood pressure and improved blood lipid profile, reducing the risk of cardiovascular events in diabetic patients.

Based on this robust clinical evidence, omega-3 fatty acid supplementation is often recommended as part of a comprehensive diabetes management strategy.

- **Marine Sterols: Early Stages of Clinical Exploration:** Clinical trials investigating the anti-diabetic effects of marine sterols are still in their infancy. However, some preliminary studies suggest potential benefits. For instance, research suggests that fucosterol supplementation may improve insulin sensitivity and glycemic control in individuals with type 2 diabetes. Further large-scale clinical trials are necessary to confirm these findings and establish the therapeutic role of marine sterols in diabetes management.

3. Challenges and Considerations: Bridging the Gap from Promise to Practice

While preclinical and early-stage clinical studies demonstrate the promising potential of marine-derived compounds for diabetes management, several challenges need to be addressed before widespread clinical application.

- **Standardization and Quality Control:** Marine-derived bioactive compounds can exhibit substantial variability in their composition and biological activity depending on the source organism, extraction methods, and processing techniques. Establishing standardized protocols for harvesting, processing, and quality control of these compounds is crucial for ensuring consistent efficacy and safety in clinical use.
- **Dosage Optimization and Delivery Systems**: Determining optimal dosages of marine-derived compounds for diabetes management is essential. Additionally, developing efficient delivery systems to ensure optimal bioavailability (absorption and utilization) within the body is necessary.
- **Safety Considerations**: Further research is needed to comprehensively assess the long-term safety of marine-derived compounds, particularly for individuals with pre-existing medical conditions or those taking other medications.
- **Cost-Effectiveness**: The cost-effectiveness of marine-derived therapies needs to be evaluated to ensure their accessibility for patients with diabetes, especially in resource-limited settings.

IV. FUTURE DIRECTIONS: UNVEILING THE FULL POTENTIAL OF MARINE RESOURCES FOR DIABETES MANAGEMENT

The exploration of marine resources for diabetes management holds immense promise for the future of diabetes care. Here, we will discuss key areas for future research and development [2]:

- **Identification and Characterization of Novel Bioactive Compounds**: Ongoing research efforts should focus on identifying and characterizing novel bioactive compounds from marine sources with potential anti-diabetic properties. This exploration could involve advanced screening techniques and functional assays to identify promising candidates.
- **Mechanism of Action Studies**: Further studies are required to elucidate the precise

mechanisms by which marine-derived compounds exert their anti-diabetic effects. This understanding will pave the way for the development of targeted therapeutic strategies.

- **Combination Therapies [10,12,13]:** Investigating the potential benefits of combining marine-derived compounds with existing diabetes medications could lead to more effective and personalized treatment approaches.
- **Large-Scale Clinical Trials:** Well-designed, large-scale clinical trials are necessary to confirm the efficacy and safety of marine-derived compounds for diabetes management in diverse patient populations. These trials should assess long-term outcomes and potential adverse effects [17].
- **Sustainability and Environmental Considerations**: Sustainable harvesting practices and responsible resource management are paramount to ensure the long-term availability of marine resources while minimizing environmental impact.

V. SUMMARY

The vast potential of marine resources for diabetes management is gradually being unveiled. Marine-derived compounds, including polysaccharides, polyphenols, peptides, omega-3 fatty acids, and sterols, hold promise for improving glycemic control, enhancing insulin sensitivity, and reducing the risk of diabetes complications. While preclinical and early-stage clinical studies provide encouraging evidence, further research is necessary to address challenges related to standardization, dosage optimization, delivery systems, and cost-effectiveness. Continued exploration in these areas will pave the way for the integration of marine-derived therapies into comprehensive diabetes management strategies, ultimately improving the lives of millions living with this chronic condition.

1. Future Outlook

The future of diabetes management appears increasingly promising with the potential of marine resources playing a significant role. As research delves deeper into the ocean's treasure trove, we can anticipate the discovery and development of novel therapeutic agents derived from marine sources. These advancements, coupled with ongoing efforts to refine existing therapies, offer hope for a future where diabetes can be effectively managed, improving the well-being and quality of life for individuals living with this condition.

2. Additional Considerations

- Patient Education and Awareness: Raising awareness among healthcare professionals and patients regarding the potential benefits and limitations of marine-derived therapies for diabetes management is crucial.
- Integration with Lifestyle Modifications: Marine-derived compounds are not intended to replace established diabetes management strategies like diet, exercise, and weight management. They should be considered as complementary therapies to enhance overall outcomes [5].
- Regulatory Frameworks: Developing clear regulatory frameworks for the development, approval, and marketing of marine-derived therapies for diabetes will ensure patient safety and product quality.

REFERENCES

[1] A.A. El Gamal, Biological importance of marine algae, Saudi Pharmaceutical Journal 18(1) (2010)
[2] A.D. Association, Standards of medical care in diabetes, Diabetes care 28(suppl 1) (2005) s4-s36.
[3] A. O'sullivan, Y. O'Callaghan, M. O'Grady, B. Queguineur, D. Hanniffy, D. Troy, J. Kerry, N .O'Brien, In vitro and cellular antioxidant activities of seaweed extracts prepared from five brown seaweeds harvested in spring from the west coast of Ireland, Food Chemistry 126(3) (2011) 1064-1070.
[4] A.R. Kim, T.S. Shin, M.S. Lee, J.Y. Park, K. E. Park, N.Y. Yoon, J.S. Kim, J.S. Choi, B.C. Jang, D.S. Byun, Isolation and identification of phlorotannins from Ecklonia stolonifera with antioxidant and anti-inflammatory properties, Journal of agricultural and food chemistry 57(9) (2009) 3483-34.
[5] Madhusudan, S. Manoj, K. Rahul, C.M. Rishi, Seaweeds: A diet with nutritional, medicinal and industrial value, Research Journal of Medicinal Plant 5(2) (2011) 153-157.
[6] Choochote W, Suklampoo L, Ochaikul D. Evaluation of anti-oxidant capacities of green microalgae. J Appl Phycol. 2014;26(1):43–48. doi:10.1007/s10811-013-0084-6
[7] Sánchez-Machado, J. López-Cervantes 1J. Lopez-Hernandez, P. Paseiro-Losada, Fatty acids, total lipid, protein and ash contents of processed edible seaweeds, Food chemistry 85(3) (2004) 439-444.
[8] H. Pereira, L. Barreira, F. Figueiredo, L. Custódio, C. Vizetto-Duarte, C. Polo, E. Rešek, A. Engelen, J. Varela, Polyunsaturated fatty acids of marine macroalgae: potential for nutritional and pharmaceutical applications, Marine Drugs 10(9) (2012) 1920-1935.
[9] J. Hartweg, A. Farmer, R. Perera, R. Holman, H. Neil, Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes, Springer, 2007.
[10] J. Mann, I. De Leeuw, K. Hermansen, B. Karamanos, B. Karlström, N. Katsilambros, G. Riccardi, A. Rivellese, S. Rizkalla, G. Slama, Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus, Nutrition, Metabolism and Cardiovascular Diseases 14(6) (2004) 373-394.
[11] J.S. de Munter, F.B. Hu, D. Spiegelman, M. Franz, R.M. van Dam, Whole grain, bran, and germ intake and risk of type 2 diabetes: a prospective cohort study and systematic review, PLoS medicine 4(8) (2007) e261.
[12] Jaspars M, de Pascale D, Andersen JH, Reyes F, Crawford AD, Ianora A. The marine biodiscovery pipeline and ocean medicines of tomorrow. J Mar Biol Assoc UK. 2016;96(1):151–158. doi:10.1017/S0025315415002106
[13] Klotz U. Ziconotide- a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain- a short review. Int J Clin Pharmacol Ther. 2006; 44:478–483. doi:10.5414/CPP44478
[14] L. Summers, B. Fielding, H. Bradshaw, V. Ilic, C. Beysen, M. Clark, N. Moore, K. Frayn, Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity, Diabetologia 45(3) (2002) 369-377.
[15] L.-E. Rioux, S.L. Turgeon, M. Beaulieu, Characterization of polysaccharides extracted from brown seaweeds, Carbohydrate polymers 69(3) (2007) 530-537.
[16] Lee S-H, Ko S-C, Kang M-C, Lee DH, Jeon Y-J. Octaphlorethol A, a marine algae product, exhibits anti-diabetic effects in type 2 diabetic mice by activating AMP-activated protein kinase and upregulating the expression of glucose transporter 4. Food Chem Toxicol. 2016; 91:58–64. doi: 10.1016/j.fct.2016.02.022
[17] Lowenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013; 121:26–28. doi:10.1182/blood-2012-07- 444851
[18] M.B. Schulze, M. Schulz, C. Heidemann, A. Schienkiewitz, K. Hoffmann, H. Boeing, Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis, Archives of internal medicine 167(9) (2007) 956-965.
[19] M.C. Kang, W.A.J.P. Wijesinghe, S.H. Lee, S.M. Kang, S.C. Ko, X. Yang, N. Kang, Dieckol isolated from brown seaweed Ecklonia cava attenuates type II diabetes in db/db mouse model, Food and chemical toxicology (53) (2013) 294-298.
[20] Manikkam V, Vasiljevic T, Donkor ON, Mathai ML. A review of potential marine-derived hypotensive and anti-obesity peptides. Crit Rev Food Sci Nutr. 2016;56(1):92–112. doi:10.1080/10408398.2012.753866
[21] P. MacArtain, C.I. Gill, M. Brooks, R. Campbell, I.R. Rowland, Nutritional value of edible seaweeds, Nutrition reviews 65(12) (2007) 535-543.
[22] Pangestuti R, Kim SK. Biological activities and health benefit effects of natural pigments derived from marine algae. J Funct Foods. 2011; 3:255–266. doi: 10.1016/j.jff.2011.07.001
[23] Ruocco N, Costantini S, Guariniello S, Costantini M. Polysaccharides from the marine environment with

pharmacological, cosmeceutical and nutraceutical potential. Molecules. 2016;21(5):551–567. doi:10.3390/molecules21050551

[24] S. H. Lee, Y.J. Jeon, Anti-diabetic effects of brown algae derived phlorotannins, marine polyphenols through diverse mechanisms, Fitoterapia 86 (2013) 129-136.

[25] S.D. Anastyuk, N.M. Shevchenko, E.L. Nazarenko, P.S. Dmitrenok, T.N. Zvyagintseva, Structural analysis of a fucoidan from the brown algae Fucus evanescens by MALDI-TOF and tandem ESI mass spectrometry, Carbohydrate research 344(6) (2009) 779-787.

[26] S.H. Lee, J.S. Han, S.J. Heo, J.Y. Hwang, Y.J. Jeon, Protective effects of dieckol isolated from Ecklonia cava against high glucose-induced oxidative stress in human umbilical vein endothelial cells, Toxicology in Vitro 24(2) (2010) 375-381.

[27] Sagar S, Kaur M, Minneman KP. Antiviral lead compounds from marine sponges. Mar Drugs. 2010;8(10):2619–2638. doi:10.3390/md8102619

[28] Saleh ASM, Zhang Q, Shen Q. Recent research in antihypertensive activity of food protein-derived hydrolyzates and peptides. Crit Rev Food Sci Nutr. 2016;56(5):760–787. doi:10.1080/10408398.2012.724478

[29] Suleria HARHAR, Gobe G, Masci P, Osborne SA. Marine bioactive compounds and health promoting perspectives; innovation pathways for drug discovery. Trends Food Sci Technol. 2016; 50:44–55. doi: 10.1016/j.tifs.2016.01.019

[30] X. Pi-Sunyer, Do glycemic index, glycemic load, and fiber play a role in insulin sensitivity, disposition index, and type 2 diabetes?, Diabetes care 28(12) (2005) 2978-2979.

[31] Z. Zhang, F. Wang, X. Wang, X. Liu, Y. Hou, Q. Zhang, Extraction of the polysaccharides from five algae and their potential antioxidant activity in vitro, Carbohydrate Polymers 82(1) (2010) 118-121.

[32] Zhao C, Wu Y, Yang C, Liu B, Huang Y. Hypotensive, hypoglycaemic and hypolipidaemic effects of bioactive compounds from microalgae and marine micro-organisms. Int J Food Sci Technol. 2015; 50:1705–1717. doi:10.1111/ijfs.12860